References
- Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
- Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501–13.
- Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Jr., Dalino P, . Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008;87:168–81.
- Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G, . Compensatory activation of Akt in response to mTOR and Raf inhibitors – a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010;295:100–9.
- Couderc C, Poncet G, Villaume K, Blanc M, Gadot N, Walter T, . Targeting the PI3K/mTOR pathway in murine endocrine cell lines in vitro and in vivo effects on tumor cell growth. Am J Pathol 2011;178:336–44.